Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03043820Phase 3Completed

Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

Role: collaborator

NCT02207673Not ApplicableUnknown

A New Method for Delineation of Epileptic Brian Tissue During Epilepsy Surgery (The HFO Study)

Role: collaborator

NCT02098759Not ApplicableUnknown

Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex

Role: collaborator

NCT00217243Completed

Evoked Fields After Median and Ulnar Stimulation

Role: collaborator

All 4 trials loaded